EUVIMEDEUVIMED entdecken
Crossref

Assessment of Insulin Resistance and Glycemic Changes among Hypercholesterolemic Patients Receiving Atorvastatin: A Retrospective Observational Study

Upasana Pal

International Journal of Pharmaceutical Quality Assurance · 31.03.2026 · 17 (03)

DOI: 10.25258/ijpqa.17.3.32 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 31.03.2026. Verfasst von Upasana Pal.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Statins, particularly atorvastatin, are among the most prescribed lipid-lowering agents worldwide. While their cardiovascular benefits are well-established, growing evidence suggests that long-term atorvastatin use may adversely alter glycemic homeostasis, potentially accelerating the onset of new-onset diabetes mellitus (NODM) or worsening pre-existing glucose intolerance. Despite this pharmacological concern, data from tertiary care settings in India remain limited.

Objectives

This study aimed to evaluate glycemic status, including fasting blood glucose (FBG), postprandial blood glucose (PPBG), glycated haemoglobin (HbA1c), and insulin resistance indices, among hypercholesterolemic patients receiving atorvastatin therapy in a tertiary care hospital. Materials and Methods: A retrospective record-based study was conducted over 12 months at a tertiary care hospital. Medical records of 182 adult hypercholesterolemic patients on atorvastatin (10 mg to 40 mg daily) without baseline diabetes were analysed. Glycemic parameters were recorded at baseline, 6 months, and 12 months. Data were analysed using SPSS version 22.0 and statistical significance was set at p < 0.05.

Results

The mean age of patients was 51.4 ± 10.7 years with a male predominance (53.8%). Statistically significant increases in FBG (96.4 to 107.3 mg/dL), PPBG (128.7 to 143.5 mg/dL), HbA1c (5.3% to 5.9%), and HOMAIR (1.94 to 2.73) were observed over 12 months (p < 0.05). New-onset diabetes was detected in 14 patients (7.7%) at 12 months, with higher incidence in those receiving 40 mg atorvastatin (10.9%) compared to 10–20 mg (4.4%). Impaired fasting glucose increased from 20.9% at baseline to 39.6% at 12 months.

Conclusion

Atorvastatin therapy is associated with progressive and dose-dependent worsening of glycemic parameters in hypercholesterolemic patients. Routine glycemic surveillance should be mandated in all patients receiving atorvastatin therapy, particularly those on higher doses or with pre-existing metabolic risk factors.

Zitieren

APA

Pal, U. (2026). Assessment of Insulin Resistance and Glycemic Changes among Hypercholesterolemic Patients Receiving Atorvastatin: A Retrospective Observational Study. International Journal of Pharmaceutical Quality Assurance, 17(03). https://doi.org/10.25258/ijpqa.17.3.32

Vancouver

Pal U. Assessment of Insulin Resistance and Glycemic Changes among Hypercholesterolemic Patients Receiving Atorvastatin: A Retrospective Observational Study. International Journal of Pharmaceutical Quality Assurance. 2026;17(03). doi:10.25258/ijpqa.17.3.32

BibTeX
@article{Pal2026,
  author = {Pal, Upasana},
  title = {Assessment of Insulin Resistance and Glycemic Changes among Hypercholesterolemic Patients Receiving Atorvastatin: A Retrospective Observational Study},
  journal = {International Journal of Pharmaceutical Quality Assurance},
  year = {2026},
  volume = {17},
  number = {03},
  doi = {10.25258/ijpqa.17.3.32}
}
Kostenlos starten →